

**IND SAFETY REPORT: INITIAL WRITTEN REPORT****TO: Division of Drug Oncology Products, Center for Drug Evaluation and Research, FDA****FAX: 301-796-9845**1. IND NUMBER  
**61010**2. AGENT NAME  
**CCI-779 (temsirolimus, Torisel®)**3. DATE  
**August 22, 2011**

4. SPONSOR

**Division of Cancer Treatment and Diagnosis, National Cancer Institute**

5. REPORTER'S NAME, TITLE, AND INSTITUTION

**L. Austin Doyle, MD-Senior Investigator for Investigational Therapeutics 2, Investigational Drug Branch, CTEP, DCTD, NCI**6. PHONE NUMBER  
**301-496-1196**7. FAX NUMBER  
**301-402-0428**

8a. PROTOCOL NUMBER (AE #)

**GOG-0086P (AE# 1309898)**

8b. AE GRADE: AE

**Grade 2: Injection site reaction/extravasation changes**

9. PATIENT IDENTIFICATION

**073-0086P-024**

10. AGE

**62 years**

11. SEX

**Female**

12. DESCRIPTION OF ADVERSE EVENT

**The patient is a 62-year-old female with serous endometrial adenocarcinoma who experienced grade 2 injection site reaction/extravasation changes while on a phase 2 trial utilizing the investigational agent temsirolimus in combination with paclitaxel and carboplatin. The patient began the investigational therapy on April 6, 2011, and received her last doses of temsirolimus, paclitaxel, and carboplatin on June 29, 2011 (Cycle 5, Day 1). On July 2, 2011 (Cycle 5, Day 4), the patient presented to the emergency room with weakness. She was also dehydrated and had renal insufficiency, hypokalemia, hyponatremia, and a markedly elevated blood sugar. The physical exam revealed swelling, tenderness, and increased warmth of her left arm, where the Port-A-Cath® was placed. The patient was admitted for further evaluation. Duplex venous sonograms of the left upper extremity were performed on July 2 and July 4, 2011, but neither of them revealed evidence of deep vein thrombosis in the left arm. The swelling of the left arm was considered to be an extravasation change. Additional information has been requested from the investigational site. There is a reasonable possibility that the experience may have been caused by the drug.**

13. DOSE, ROUTE, AND SCHEDULE

**Cycle = 21 Days**

**Temsirolimus: 25 mg IV over 30 minutes on Days 1 and 8 (starting with Cycle 2 for those patients entering post surgery) × 6 cycles. Maintenance Therapy (Cycles 7+): Temsirolimus 25 mg IV over 30 minutes weekly on Days 1, 8, and 15 (Note: Patients to receive maintenance treatment until disease progression or until adverse events prohibit further therapy).**

14. DATES OF TREATMENT

**The patient began the investigational therapy on April 6, 2011, receiving the last doses of temsirolimus, paclitaxel, and carboplatin on June 29, 2011 (Cycle 5, Day 1).**

15. ACCRUAL AND IND EXPERIENCE

**Number of patients enrolled in NCI-sponsored clinical trials using temsirolimus = 2826.**

**There have been 5 other cases of injection site reaction/extravasation changes reported to the NCI through AdEERS as serious adverse events for temsirolimus.**

16. COMMENTS

**Paclitaxel: 175 mg/m<sup>2</sup> IV over 3 hours on Day 1 × 6 cycles; Carboplatin: AUC = 5 IV over 30 minutes on Day 1 × 6 cycles**

**AT THIS TIME, NO OTHER INFORMATION IS AVAILABLE. IF UPON FURTHER INVESTIGATION RELEVANT INFORMATION BECOMES AVAILABLE, THEN A FOLLOW-UP REPORT WILL BE SUBMITTED IN ACCORDANCE WITH 21CFR 312.32 (d) (2).**

**DISCLAIMER per 21 CFR 312.32 (e): THIS SAFETY REPORT DOES NOT NECESSARILY REFLECT A CONCLUSION OR ADMISSION BY THE CTEP IDB SENIOR INVESTIGATOR/SPONSOR THAT THE INVESTIGATIONAL AGENT/THERAPY CAUSED OR CONTRIBUTED TO THE ADVERSE EXPERIENCE BEING REPORTED.**

0002